Breast Cancer

, 11:221 | Cite as

Breast cancer and the NSABP-B32 sentinel node trial

  • David Krag
  • Seth Harlow
  • Thomas Julian
Review Article

Key words

Breast Cancer Lymph Sentinel nodes 


  1. 1).
    Cabanes PA, Salmon RJ, Vilcoq JR,et al: Value of axillary dissection in addition to lumpectomy and radiotherapy in early breast cancer. The Breast Carcinoma Collaborative Group of the Institut Curie.Lancet 339:1245–1248, 1992.PubMedCrossRefGoogle Scholar
  2. 2).
    Fisher B, Redmond C, Fisher ER,et al: Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation.N Engl J Med 312:674–681, 1985.PubMedGoogle Scholar
  3. 3).
    Hayward JI: The Guy’s Hospital trials on breast conservation. In: Harris JR, Hellman S, Silen W, eds. Conservative Management of Breast Cancer: New Surgical and Radiotherapeutic Techniques. Philadelphia, J.B. Lippincott, pp77–90, 1983.Google Scholar
  4. 4).
    Atkins H, Hayward JL, Klugman DJ, Wayte AB: Treatment of early breast cancer: a report after ten years of a clinical trial.Br Med J 2:423–429, 1972.PubMedCrossRefGoogle Scholar
  5. 5).
    Langlands AO, Prescott RJ, Hamilton T: A clinical trial in the management of operable cancer of the breast.Br J Surg 67:170–174, 1980.PubMedCrossRefGoogle Scholar
  6. 6).
    Johansen H, Kaae S, Schiodt T: Simple mastectomy with postoperative irradiation versus extended radical mastectomy in breast cancer. A twenty-five-year follow-up of a randomized trial.Ada Oncol 29:709–715, 1990.CrossRefGoogle Scholar
  7. 7).
    Orr RK: The impact of prophylactic axillary node dissection on breast cancer survival-a Bayesian meta-analysis.Ann Surg Oncol 6:109–116, 1999.PubMedCrossRefGoogle Scholar
  8. 8).
    Krag DN, Single RM: Breast cancer survival according to number of nodes removed.Ann Surg Oncol 10:1152–1159, 2003.PubMedCrossRefGoogle Scholar
  9. 9).
    Bland KI, Scott-Conner CE, Menck H, Winchester DP: Axillary dissection in breast-conserving surgery for stage I and II breast cancer: a National Cancer Data Base study of patterns of omission and implications for survival.J Am Coll Surg 188:586–595; discussion 95-96, 1999.PubMedCrossRefGoogle Scholar
  10. 10).
    van der Wal B, Butzelaar R, van der Meij S, Boermeester M: Axillary lymph node ratio and total number of removed lymph nodes: predictors of survival in stage I and II breast cancer.EurJ Surg Oncol 28:481, 2002.CrossRefGoogle Scholar
  11. 11).
    Sosa JA, Diener-West M, Gusev Y,et al: Association between extent of axillary lymph node dissection and survival in patients with stage I breast cancer.Ann Surg Oncol 5:140–149, 1998.PubMedCrossRefGoogle Scholar
  12. 12).
    Mathiesen O, Carl J, Bonderup O, Panduro J: Axillary sampling and the risk of erroneous staging of breast cancer. An analysis of 960 consecutive patients.Acta Oncol 29:721–725, 1990.PubMedCrossRefGoogle Scholar
  13. 13).
    Axelsson CK, Mouridsen HT, Zedeler K: Axillary dissection of level I and II lymph nodes is important in breast cancer classification. The Danish Breast Cancer Cooperative Group (DBCG).Eur J Cancer 28A(8– 9):1415–1418, 1992.PubMedCrossRefGoogle Scholar
  14. 14).
    Le Voyer TE, Sigurdson ER, Hanlon AL,et al: Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of inter-group trial INT-0089.J Clin Oncol 21:2912–2919, 2003.PubMedCrossRefGoogle Scholar
  15. 15).
    Tepper JE, O’Connell MJ, Niedzwiecki D,et al: Impact of number of nodes retrieved on outcome in patients with rectal cancer.J Clin Oncol 19:157–163, 2001.PubMedGoogle Scholar
  16. 16).
    Chan AD, Essner R, Wanek LA, Morton DL: Judging the therapeutic value of lymph node dissections for melanoma.J Am Coll Surg 191:16–22; discussion-3, 2000.PubMedCrossRefGoogle Scholar
  17. 17).
    Saphir O, Amromin G: Obscure axillary lymph-node metastasis in carcinoma of the breast.Cancer 1:238–241, 1948.PubMedCrossRefGoogle Scholar
  18. 18).
    Weaver DL, Krag DN, Ashikaga T, Harlow SP, O’Connell M: Pathologic analysis of sentinel and nonsentinel lymph nodes in breast carcinoma: a multicenter study.Cancer 88:1099–1107, 2000.PubMedCrossRefGoogle Scholar
  19. 19).
    Schoenfeld A, Luqmani Y, Sinnett HD, Shousha S, Coombes RC: Keratin 19 mRNA measurement to detect micrometastases in lymph nodes in breast cancer patients.Br J Cancer 74:1639–1642, 1996.PubMedGoogle Scholar
  20. 20).
    Lockett MA, Baron PL, O’Brien PH,et at: Detection of occult breast cancer micrometastases in axillary lymph nodes using a multimarker reverse transcriptase-polymerase chain reaction panel.J Am Coll Surg 187:9–16, 1998.PubMedCrossRefGoogle Scholar
  21. 21).
    Heller R, Becker J, Wasselle J,et al: Detection of submicroscopic lymph node metastases in patients with melanoma.Arch Surg 126:1455–1459; discussion 9-60, 1991.PubMedGoogle Scholar
  22. 22).
    Hall JC, Platell C, Hall JL: Surgery on trial: an account of clinical trials evaluating operations.Surgery 124:22–27, 1998.PubMedGoogle Scholar
  23. 23).
    Bonenkamp JJ, Hermans J, Sasako M, van De Velde CJ: Quality control of lymph node dissection in the Dutch randomized trial of D1 and D2 lymph node dissection for gastric cancer.Gastric Cancer 1:152–159, 1998.PubMedCrossRefGoogle Scholar
  24. 24).
    Leong SP, Donegan E, Heffernon W, Dean S, Katz JA: Adverse reactions to isosulfan blue during selective sentinel lymph node dissection in melanoma.Ann Surg Oncol 7:361–366, 2000.PubMedCrossRefGoogle Scholar
  25. 25).
    Albo D, Wayne JD, Hunt KK,et al: Anaphylactic reactions to isosulfan blue dye during sentinel lymph node biopsy for breast cancer.Am J Surg 182:393–398, 2001.PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Breast Cancer Society 2004

Authors and Affiliations

  1. 1.Department of Surgical OncologyUniversity of Vermont College of Medicine Given Bldg Rm E309 BurlingtonVTUSA
  2. 2.Department of SurgeryUniversity of Vermont College of MedicineUSA
  3. 3.Department of Human OnocologyDrexel School of Medicine Allegheny General HospitalUSA

Personalised recommendations